Lab1636 and Harvard University RFA on Rare Genetic Diseases

October 27, 2020

Harvard’s Office of Technology Development ( is pleased to announce a Request for Applications (RFA) under the strategic research alliance between Harvard University and Lab1636. This 2020 RFA with Lab1636 and Harvard University is seeking proposals to develop innovative therapeutic strategies for Rare Genetic Diseases. Letter of Intents (LOIs) are due December 4, 2020 at 5:00 pm.

PIs must be faculty of FAS, SEAS, HMS, etc.  Postdocs and research scientists can apply jointly with a PI.

Harvard University and Deerfield Management, a healthcare investment firm, established a major strategic R&D alliance in 2019 to speed the development and translation of biomedical and life-science innovations into transformative treatments that can improve life, health, and medical care. Through a newly launched company called Lab1636, Deerfield committed up to $100 million in initial funding to support the alliance.
The attached document provides more details on the topic of interest, LOI submission, review and selection process, eligibility and collaborations, and award terms and conditions.
Please reach out to your Business Development contact within OTD or contact us at if you need any additional information. We look forward to hearing from you!

2020_lab1636_harvard_rare_genetic_diseases_rfa_-_guidelines.pdf273 KB
See also: 2020, Announcement